Study of CTA313 in autoimmune diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new drug called CTA313 for people with certain autoimmune diseases like lupus, multiple sclerosis, or autoimmune encephalitis. It aims to see if the drug is safe and effective for these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have adequate organ function as determined by your doctor.
- You must have a confirmed diagnosis of refractory lupus, primary or secondary progressive MS, or autoimmune encephalitis.
- You must not have had a heart attack, heart failure (class III or IV), or heart procedures within the last 12 months.
- You must not have severe central nervous system disorders that could interfere with study participation.
- You must not have active cancer or a history of cancer that was not cured at least 5 years ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
This study tests a new treatment, CRT-402, for people with certain autoimmune diseases who have not improved with standard treatments. It aims to find out if this treatment is safe and if it helps control symptoms.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.